AutoFlight’s five-tonne Matrix bets on heavy payloads and regional range to prove the case for electric flight
Updated
March 17, 2026 1:02 AM
A multiroter flying through a blue sky. PHOTO: UNSPLASH
The nascent industry of electric vertical takeoff and landing (eVTOL) aircraft has long been defined by a specific set of limitations: small payloads, short distances and a primary focus on urban air taxis. AutoFlight, a Chinese aviation startup, recently moved to shift that narrative by unveiling "Matrix," a five-tonne aircraft that represents a significant leap in scale for electric aviation.
In a demonstration at the company’s flight test center, the Matrix completed a full transition flight—the technically demanding process of switching from vertical lift-off to forward wing-born flight and back to a vertical landing. While small-scale drones and four-seat prototypes have become increasingly common, this marks the first time an electric aircraft of this mass has successfully executed the maneuver.
The sheer scale of the Matrix places it in a different category than the "flying cars" currently being tested for hops over city traffic. With a maximum takeoff weight of 5,700 kilograms (roughly 12,500 pounds), the aircraft has the footprint of a traditional regional turboprop, boasting a 20-meter wingspan. Its size allows for configurations that the industry has previously struggled to accommodate, including a ten-seat business class cabin or a cargo hold capable of carrying 1,500 kilograms of freight.
This increased capacity is more than just a feat of engineering; it is a direct attempt to solve the financial hurdles that have plagued the sector, specifically addressing the skepticism industry analysts have often expressed regarding the economic viability of smaller eVTOLs. These critics frequently cite the high cost of operation relative to the low passenger count as a barrier to entry.
AutoFlight’s founder and CEO, Tian Yu, suggested the Matrix is a direct response to those concerns. “Matrix is not just a rising star in the aviation industry, but also an ambitious disruptor,” Yu stated. “It will eliminate the industry perception that eVTOL = short-haul, low payload and reshape the rules of eVTOL routes. Through economies of scale, it significantly reduces transportation costs per seat-kilometer and per ton-kilometer, thus revolutionizing costs and driving profitability.”
To achieve this, the aircraft utilizes a "lift and cruise" configuration. In simple terms, this means the plane uses one set of dedicated rotors to lift it off the ground like a helicopter, but once it reaches a certain speed, it uses a separate propeller to fly forward like a traditional airplane, allowing the wings to provide the lift. This design is paired with a distinctive "triplane" layout—three layers of wings—and a six-arm structure to keep the massive frame stable.
These features allow the Matrix to serve a variety of roles. For the "low-altitude economy" being promoted by Chinese regulators, the startup is offering a pure electric model with a 250-kilometer range for regional hops, alongside a hybrid-electric version capable of traveling 1,500 kilometers. The latter version, equipped with a forward-opening door to fit standard air freight containers, targets a logistics sector still heavily reliant on carbon-intensive trucking.
However, the road to commercial flight remains a steep one. Despite the successful flight demonstration, AutoFlight faces the same formidable headwinds as its competitors, such as a complex global regulatory landscape and the rigorous demands of airworthiness certification. While the Matrix validates the company's high-power propulsion, moving from a test-center demonstration to a commercial fleet will require years of safety data.
Nevertheless, the debut of the Matrix signals a maturation of the startup’s ambitions. Having previously developed smaller models for autonomous logistics and urban mobility, AutoFlight is now betting that the future of electric flight isn't just in avoiding gridlock, but in hauling the weight of regional commerce. Whether the infrastructure and regulators are ready to accommodate a five-tonne electric disruptor remains the industry's unanswered question.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.